

Terumo Announces Voting Results for the Election of Directors

TOKYO, JAPAN – June 22, 2021 – Terumo Corporation (TSE: 4543) hereby announces the voting results for the election of directors held at the Annual General Meeting of Shareholders today. All candidates listed on the May 12 announcement were elected as directors of Terumo Corporation.

1. Directors

(Excluding directors who serve as Audit and Supervisory Committee Members)

Name	New position	Current position
Takayoshi Mimura	Chairman of the Board	Same as on the left
Shinjiro Sato	President and CEO	Same as on the left
Toshiaki Takagi	Director and Senior Managing Executive Officer	Same as on the left
Shoji Hatano	Director and Managing Executive Officer	Same as on the left
Kyo Nishikawa	Director and Managing Executive Officer	Same as on the left
Yukiko Kuroda	Independent Director	Same as on the left
Hidenori Nishi	Independent Director	Same as on the left
Keiya Ozawa	Independent Director	(New candidate)

2. Directors who serve as Audit and Supervisory Committee Members

Name	New position	Current position
Takanori Shibazaki	Director who serves as an Audit/Supervisory Committee Member	Senior Executive Officer
Masaichi Nakamura	Independent Director who serves as an Audit/Supervisory Committee Member	Same as on the left
Soichiro Uno	Independent Director who serves as an Audit/Supervisory Committee Member	Same as on the left

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.